Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]
This could be a key move for future growth.
Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...
Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth signals, including the $1 billion purchase of RayThera Inc., an FDA Breakthrough Therapy tag for its drug candidate Salanersen, and a recent analyst upgrade.
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season.
Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the stock closing at US$196.58. That level sits against a backdrop of mixed short and longer term returns. See our latest analysis for Biogen. Short term momentum for Biogen looks softer, with the 1 day and 7 day share price returns both slightly negative, while the 1 month and year to date share price returns remain positive and the 1 year total shareholder return is...
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 bill
The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.